Twist Bioscience (NASDAQ:TWST) CAO Robert Werner Sells 7,000 Shares

Twist Bioscience Corporation (NASDAQ:TWST) CAO Robert Werner sold 7,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $45.65, for a total value of $319,550.00. Following the sale, the chief accounting officer directly owned 58,738 shares of the company’s stock, valued at $2,681,389.70. This represents a 10.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Twist Bioscience Stock Up 1.7%

NASDAQ:TWST opened at $47.92 on Friday. The company has a quick ratio of 3.33, a current ratio of 3.78 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $54.26. The stock’s fifty day simple moving average is $36.54 and its 200-day simple moving average is $31.94. The firm has a market capitalization of $2.94 billion, a P/E ratio of -37.24 and a beta of 2.24.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The firm had revenue of $103.70 million for the quarter, compared to the consensus estimate of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.Twist Bioscience’s revenue for the quarter was up 16.9% on a year-over-year basis. Equities research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently made changes to their positions in the company. Campbell & CO Investment Adviser LLC boosted its position in Twist Bioscience by 227.6% in the third quarter. Campbell & CO Investment Adviser LLC now owns 47,200 shares of the company’s stock valued at $1,328,000 after buying an additional 32,792 shares in the last quarter. Baillie Gifford & Co. boosted its holdings in shares of Twist Bioscience by 62.8% during the 3rd quarter. Baillie Gifford & Co. now owns 1,262,739 shares of the company’s stock valued at $35,533,000 after acquiring an additional 487,052 shares in the last quarter. Thrivent Financial for Lutherans grew its position in Twist Bioscience by 14.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,463,085 shares of the company’s stock worth $41,171,000 after acquiring an additional 184,726 shares during the last quarter. New York State Common Retirement Fund increased its holdings in Twist Bioscience by 14.0% in the 3rd quarter. New York State Common Retirement Fund now owns 584,694 shares of the company’s stock worth $16,453,000 after purchasing an additional 71,777 shares in the last quarter. Finally, American Century Companies Inc. raised its position in Twist Bioscience by 13.2% in the second quarter. American Century Companies Inc. now owns 864,384 shares of the company’s stock valued at $31,801,000 after purchasing an additional 100,978 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on TWST shares. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Robert W. Baird set a $50.00 price objective on shares of Twist Bioscience in a research report on Tuesday. Evercore ISI raised their price objective on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Tuesday. Stephens started coverage on Twist Bioscience in a report on Monday, November 3rd. They set an “overweight” rating and a $41.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $45.88.

Trending Headlines about Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Company guidance was lifted, with coverage highlighting stronger demand tied to AI-related customers but also noting execution risks; the guidance boost is being read as evidence of improving end-market demand. Twist Bioscience Guidance Lift Puts AI Demand And Risks In Focus
• Positive Sentiment: An analyst price target was raised 20% to $48.35, signaling increased bullishness from at least one wall‑street watcher and supporting the recent share-price momentum. TWST price target increased by 20%
• Neutral Sentiment: A recent valuation piece assesses TWST after its run-up and discusses whether the current share price already reflects improved fundamentals and the guidance lift; useful for investors re-evaluating upside vs. valuation risk. Assessing Twist Bioscience Valuation
• Negative Sentiment: CEO Emily Leproust sold 5,001 shares at an average $46.58 (≈0.57% reduction in her stake). Insider sales by the CEO can spook investors even if they are routine. CEO sale filing
• Negative Sentiment: CAO Robert F. Werner reported larger sales: 7,000 shares at an average $45.65 (≈10.65% reduction in one filing) plus an earlier 175-share sale; these are meaningful reductions from a senior finance officer. CAO sale filing
• Negative Sentiment: Other insiders, including SVP Paula Green (1,194 shares) and insider Dennis Cho (1,099 shares), also sold stakes at ~ $46.58, adding to overall insider selling activity this week. SVP sale filing Insider sale filing

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.